Teleconference: Breast Cancer Prevention: Raloxifene as Effective as Tamoxifen with Fewer Side Effects Raloxifene improved its effectiveness against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen. Full results of the Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention are discussed in this press conference by a panel of experts.
Download* the mp3 of the teleconference (29.3 MB, 42:41 minutes)
Read the article in Cancer Prevention Research.
Read the news release Breast Cancer Prevention: Raloxifene as Effective as Tamoxifen with Fewer Side Effects.
*On a PC, right mouse click on the "Download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.
Page updated: April 19, 2010